Ozempic Economics: What We’re Getting Wrong about GLP-1 Drugs
From cost effectiveness to fiscal return
A man in his early fifties with type 2 diabetes suffers a preventable heart attack and leaves the workforce. His employer loses an experienced worker. The health system absorbs the cost of acute care and long-term complications. Disability payments replace income.
We treat these outcomes as separate health and economic problems. They are not. And they are preventable with GLP-1 drugs.
We are making two simultaneous errors about GLP-1 drugs. We are calling a longevity drug a lifestyle drug and an economic investment a healthcare cost. These errors will cost lives and money.
As budgets shift to defence, all countries face fiscal pressures. Meanwhile, global health is entering a new era—one defined by falling development assistance and increasing reliance on domestic resources.
In this new era, governments should look to interventions that both save lives and pay for themselves. GLP-1 drugs meet that test in many countries. But we don’t yet see them that way.
To address this gap, I modelled the fiscal case for GLP-1 drugs in 55 countries. This blog provides framing and overview; the next, a worked example of Canada; and the final one, a global perspective generalizing to other countries. A detailed technical paper is appended below.
The headline: $1.1 trillion in cumulative fiscal surplus through 2050. But there are so many interesting details, which I will highlight in this GLP-1 blog trilogy.
They are not only lifestyle drugs
Natasha Loder and I described the benefits of GLP-1s in global health as “mind-bogglingly large.” In a modelling study based on clinical trial evidence, David Brook and I estimated that widespread global access to GLP-1 receptor agonists could save between 2.1 and 3.1 million lives per year among people with type 2 diabetes or obesity. These numbers are comparable to childhood vaccines and antiretroviral drugs for HIV. Those interventions triggered global campaigns and political urgency. GLP-1s have not, despite comparable potential impact.
The timing matters. Generic semaglutide is now entering global markets. Health Canada approved the first generic in April 2026 — Canada is the first G7 country with a generic; India’s market is already at around US $15 per month; patents will have lapsed in countries representing nearly half the global obesity burden by year-end.
GLP-1s are not a silver bullet. They complement, not replace, other interventions. The existence of complementary measures is not an argument against an intervention that could save millions of lives. We did not reject statins because they do not address diet.
Governments can either treat GLP-1s as a niche pharmaceutical expense and underinvest, or recognize them as a large-scale economic opportunity and act. The choice over the next few years will determine whether these gains are realized or lost.
This is not simply a cost
The Commission on Macroeconomics and Health argued in 2001 that health is an economic investment, not merely a social expenditure. It was right. It did not specify which interventions generate fiscal returns. Only a handful do. GLP-1s are on that list.
The standard framework for evaluating drugs — cost per quality-adjusted life year — was designed for allocating health budgets, not for assessing investments that affect GDP and public finances. Applied to GLP-1s at brand prices, the drugs look expensive and debatable. That conclusion is not wrong. It is incomplete.
A different lens produces a different answer, especially as prices drop. Tony Blair Institute analysis estimates a UK GDP gain of 0.3% at five years and 0.55% at ten years, with a fiscal surplus of £52 billion by 2050. Applying similar logic to Canada, my modelling suggests GDP gains of 0.15% at maturity and CAN $72 billion cumulative fiscal surplus by 2050.
Programme design matters. For example, the lifelong paradox: one counterintuitive finding is that lifelong treatment provides a much stronger fiscal case than a defined period of use, as some guidelines require, because the health care savings compound. Commentators complaining about lifelong use are not only clinically wrong, they are also fiscally wrong.
GLP-1s are not just a health intervention. They are also an economic intervention. Their effects flow through improved labour force productivity and reduced healthcare costs. They make money for treasuries. That is what current frameworks miss.
The error: we are misclassifying a fiscal investment as a healthcare cost.
How do GLP-1s compare with other health interventions?
Health interventions vary in fiscal-return profile. Tobacco control and childhood vaccination deliver exceptional returns, but most gains are already captured in high-income countries. Sugar-sweetened beverage taxes generate revenue and modestly reduce consumption, but produce limited GDP effects. Health workforce investments are essential, but their economic effects are diffuse and difficult to trace directly to fiscal return. Early childhood development pays off, but over decades.
GLP-1s deliver lives saved and fiscal returns within a policy-relevant period. In a time of constrained public finance, that distinction matters.
The portfolio problem
Governments are making a portfolio mistake.
They are overweight long-term, high-variance bets — sovereign AI, defence industrial strategy, major infrastructure projects — and underweight higher-certainty investments in human capital.
GLP-1s could fill that gap.
Think of a fund manager who owns venture capital and infrastructure but no investment-grade bonds. That is the current public investment portfolio. GLP-1s are the bonds.
We have seen this shift before. Childcare was long treated as social spending. When the economics became clear — through increased labour force participation — it was reclassified as economic infrastructure. The underlying reality did not change. The framing did. Policy followed.
GLP-1s require the same shift. Until they are seen as part of the core economic portfolio, they will remain systematically underinvested.
The economic case globally
The logic extends globally — but with limits. Across 55 countries I modelled, the cumulative fiscal opportunity is approximately $1.1 trillion by 2050. It varies sharply by national income, drug price, and structural conditions — wages and the informal economy (to capture labour market productivity) and public funding of health care (to capture reduced health costs).
Extrapolating across 189 World Bank member countries: GLP-1s offer a positive fiscal case in essentially all high-income countries, roughly half of upper middle-income countries, very few lower middle-income countries, and no low-income countries. About 80 to 95 countries in total. The lives-saved case is universal. The fiscal-investment case is structurally bounded — by tax capacity, public share of health spending, and obesity prevalence.
Where the fiscal case does not apply, GLP-1 access remains a question of clinical, humanitarian, and equity priority — financed through employer-sponsored coverage, self-pay, private insurance, or donor mechanisms.
From imagination to action
The failure to act on GLP-1s is not a failure of clinical evidence. It is a failure of imagination to see the fiscal effects worldwide.
Global economic shifts will force a more disciplined approach: one that distinguishes health interventions by where their fiscal-investment case applies and finances the rest through other architectures. GLP-1s are the first major test of that shift in high-income and upper-middle-income countries.
I want to re-emphasize that no fiscal case does not mean no case. It doesn’t even mean government shouldn’t fund it. It just means the drug doesn’t pay for itself through government fiscal channels. Lives are still saved treating individuals with specific indications. Alternative financing paths exist.
Although global health, by definition, does implicate every country in the world, I was hoping the GLP-1 fiscal math would extend to more countries at lower national incomes. But the analysis also shines light on the structural issues that prevent some upper-middle and lower-middle income countries from capitalizing on the GLP-1 fiscal dividend. I am exploring other innovations with stronger fiscal profiles in countries lower in national income to develop the broader concept of Fiscally Positive Health.
As Proust put it, “The only true voyage of discovery, the only fountain of Eternal Youth, would be not to visit strange lands but to possess other eyes…”
This is the first blog in a series. The next post is a worked example — Canada in detail — including how the programme should be designed and how it sits in the public investment portfolio. The third generalizes globally across 55 countries.
Disclosures: I own shares in Eli Lilly and Lir Life Sciences. I used AI (Claude from Anthropic) in economic modelling and to assist with research and drafting; the ideas and judgments are my own and I take full responsibility for them.
Thank you to Ilaria Calvello of the Tony Blair Institute for Global Change for reviewing an earlier version of the technical paper.
Here is the detailed technical paper:
Excellent article with clear compelling arguments.
The voice of reason and logic in Global Health